A lack of reliable, high-throughput platforms to identify safe therapeutic candidates slows drug discovery efforts for chronic intestinal diseases. To solve this problem, researchers have developed human stem cell-based platforms to recreate the intestinal epithelium. Such intestine-on-a-chip strategies create physiological representatives of the human gut, allowing researchers to reliably characterize gastrointestinal disease mechanisms and screen for safe, effective therapeutic candidates. In this webinar, brought to you by Altis, Bill Thelin, PhD, Chief Scientific Officer will describe how RepliGut® provides an ideal intestine-on-a-chip platform to support early-stage drug development.
Topics to be covered
• Applying human primary intestinal cultures to accelerate drug discovery
• Technological advances to model complex chronic gastrointestinal disease
Bill Thelin, PhD
Chief Scientific Officer, Altis Biosystems
Bill Thelin is the chief scientific officer at Altis Biosystems. He has more than 15 years of drug development experience, overseeing preclinical research from discovery to IND-filing. Prior to joining Altis, he researched epithelial ion channel and receptor pharmacology, mucosal disease, and targeted drug discovery. Thelin previously served as vice president of research at Parion Sciences. In his tenure at Parion, he helped build a portfolio of novel, first-in-class therapeutic programs for pulmonary and ophthalmic diseases. He received a PhD in cell biology at the University of North Carolina and was a postdoctoral fellow with Richard Boucher at the UNC Cystic Fibrosis Center.